HC Wainwright Reaffirms “Buy” Rating for ImmunoPrecise Antibodies (NASDAQ:IPA)

HC Wainwright restated their buy rating on shares of ImmunoPrecise Antibodies (NASDAQ:IPA) in a report released on Tuesday, Benzinga reports. HC Wainwright currently has a $9.00 price target on the stock. HC Wainwright also issued estimates for ImmunoPrecise Antibodies’ Q2 2025 earnings at ($0.05) EPS, Q3 2025 earnings at ($0.07) EPS, FY2025 earnings at ($0.30) EPS, Q1 2026 earnings at ($0.08) EPS, Q2 2026 earnings at ($0.02) EPS, Q3 2026 earnings at ($0.04) EPS, Q4 2026 earnings at ($0.02) EPS, FY2026 earnings at ($0.16) EPS, FY2027 earnings at ($0.01) EPS, FY2028 earnings at $0.14 EPS and FY2029 earnings at $0.32 EPS.

Separately, Benchmark decreased their price objective on ImmunoPrecise Antibodies from $5.00 to $3.00 and set a speculative buy rating for the company in a report on Wednesday, August 14th.

ImmunoPrecise Antibodies Stock Performance

Shares of IPA stock opened at $0.67 on Tuesday. The stock has a market capitalization of $17.63 million, a price-to-earnings ratio of -1.61 and a beta of 0.10. ImmunoPrecise Antibodies has a one year low of $0.53 and a one year high of $2.60. The company’s 50-day simple moving average is $0.79 and its 200-day simple moving average is $1.09. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.15 and a current ratio of 1.41.

ImmunoPrecise Antibodies (NASDAQ:IPA) last released its earnings results on Monday, July 29th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.42). ImmunoPrecise Antibodies had a negative return on equity of 57.05% and a negative net margin of 110.66%. The firm had revenue of $4.76 million for the quarter, compared to the consensus estimate of $4.92 million. Equities analysts anticipate that ImmunoPrecise Antibodies will post -0.25 earnings per share for the current fiscal year.

Hedge Funds Weigh In On ImmunoPrecise Antibodies

An institutional investor recently raised its position in ImmunoPrecise Antibodies stock. Renaissance Technologies LLC grew its position in shares of ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) by 70.0% during the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 63,910 shares of the company’s stock after purchasing an additional 26,310 shares during the quarter. Renaissance Technologies LLC owned 0.24% of ImmunoPrecise Antibodies worth $65,000 as of its most recent filing with the SEC. 6.70% of the stock is owned by hedge funds and other institutional investors.

ImmunoPrecise Antibodies Company Profile

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes.